Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus BacteremiaDerazantinib in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic CholangiocarcinomaCeftobiprole in the Treatment of Pediatric Patients With PneumoniaCeftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
P859
description
bedrijf in Zwitserland
@nl
company
@en
name
Basilea Pharmaceutica
@de
Basilea Pharmaceutica
@en
Basilea Pharmaceutica
@fr
Basilea Pharmaceutica
@nl
Basilea藥廠
@zh
巴塞利亚药业
@zh-hans
巴塞利亞藥業
@zh-hant
type
label
Basilea Pharmaceutica
@de
Basilea Pharmaceutica
@en
Basilea Pharmaceutica
@fr
Basilea Pharmaceutica
@nl
Basilea藥廠
@zh
巴塞利亚药业
@zh-hans
巴塞利亞藥業
@zh-hant
altLabel
巴塞利亚药业
@zh
prefLabel
Basilea Pharmaceutica
@de
Basilea Pharmaceutica
@en
Basilea Pharmaceutica
@fr
Basilea Pharmaceutica
@nl
Basilea藥廠
@zh
巴塞利亚药业
@zh-hans
巴塞利亞藥業
@zh-hant
P646
P1056
P1454
P159
P17
P213
0000 0004 0508 8793
P214
184145858179823022538
P2427
grid.418234.8
P31
P3500
P571
2000-01-01T00:00:00Z
P646
/m/03c91w7
P6782
P946
CH0011432447